Skip to content
Get in Touch

Start a Conversation.

Whether you have a specific project in mind or you're still evaluating whether organoids are the right tool — we're worth a conversation.

Reach Us Directly

Address

Official

Scheelevägen 1
223 63 Lund, Sweden

Lab

Scheelevägen 2
22363 Lund, Sweden

✓ All enquiries answered within 2 business days.

✓ Project feasibility assessed within 5 business days.

✓ NDA available before any scientific details are shared.

Or submit a detailed project enquiry →
Book a Call

Schedule a Discovery Call

Pick a time that works for you — no preparation needed.

Book a Meeting →(Send a request)
Common Questions

Before You Write, We May Have Already Answered It.

Yes. While we are based in Lund, Sweden, we work with international pharma and biotech companies across Europe and beyond. Clinical tissue can be shipped to our facility under validated conditions, and all reporting is delivered digitally.

We provide a detailed tissue collection protocol at project kickoff. Fresh biopsies are typically shipped in specialised transport media under specific temperature conditions. We coordinate directly with the clinical team or biobank.

No. 3DxCell provides services to pharmaceutical companies, biotech firms, academic institutions, and clinical partners. Patients interested in organoid-based treatment profiling should speak with their treating oncologist.

Standard projects typically run 3–5 weeks from tissue intake to final report. Larger cohort studies may require 8–12 weeks. Timelines are specified in the project proposal before work begins.

No. All projects are scoped and priced individually based on the number of models, compounds, assay complexity, and deliverables. We provide a formal written proposal before any commitment. The initial feasibility conversation is free.

Yes — and we encourage it. We are happy to sign a mutual NDA before any substantive scientific discussion. Contact us and we will respond within 1 business day.

Our validated model library covers colorectal, lung (NSCLC/SCLC), breast (ER+, HER2+, TNBC), pancreatic (PDAC), and bladder cancers. We also accept new indication projects where model development is part of the scope.

Yes. We work with academic groups for mechanistic studies, biomarker discovery, and platform validation projects. Academic pricing and collaboration frameworks are available.

Our assay protocols and documentation standards are designed with regulatory awareness. GLP-aligned documentation is available on request. We recommend discussing your regulatory context at project scoping.

Yes — model development for new indications is one of our Customised Solutions offerings. This involves establishing and validating a new patient-derived organoid model from fresh tissue. Contact us to discuss feasibility.